Cancerous Mutation Articles & Analysis
16 news found
They are present in approximately half of all human malignancies, including breast, colorectal, lung, liver, prostate, bladder and skin cancers. Cancer-associated TP53 gene mutations are primarily missense mutations, which result in the substitution of a single amino acid. Although hundreds of different P53 ...
The data were presented during poster sessions at the 34th Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) in Barcelona, Spain. “These early ...
At the moment, whole exome sequencing has been used successfully in the study of several monogenic genetic diseases, including Miller syndrome, Kabuki syndrome, and severe craniocerebral malformation. 2. Complex diseases For cancerous and complex diseases, highly relevant genetic mutations can also be observed by whole exome sequencing. 3. ...
This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”. DR NADINE COLLINS, CONSULTANT CLINICAL SCIENTIST IN MOLECULAR DIAGNOSTICS WHO IS BASED AT ...
(NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced updated data from an investigator-sponsored Phase 1/2a trial of oral rigosertib plus the anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab in advanced KRAS-mutated (KRAS+) non-small ...
The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. ...
Tumor specific T cells are essential in eradicating cancer cells. “Patients with advanced head and neck cancers have limited options,” said Siqing Fu, M.D., Ph.D., professor of Investigational Cancer Therapeutics and principal investigator at The University of Texas MD Anderson Cancer Center, who presented the data ...
HOOKIPA’s pipeline includes its wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. ...
HOOKIPA’s pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. ...
HOOKIPA’s pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. ...
(NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive preclinical data demonstrating potent T cell responses, potential novel combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers. The results ...
Emily Hinchcliff (now at Northwestern University Cancer Center), the lead author of the report, noted that based on observations in two exceptional survivors, her team became interested in survival outcomes in patients with inactivating somatic tumor mutations in PPP2R1A, the major scaffold subunit of the protein phosphatase 2A (PP2A) multimeric enzyme. ...
” Mutant RAS is the most common cancer oncogene, present in one quarter of all cancers. It acts as a “hub” that activates multiple effector pathways to promote cancer growth. ...
Levy has devoted her career to developing systems to support data-driven decision-making in cancer care and research. She has contributed to more than 90 publications on cancer and led the development of My Cancer Genome, an international knowledge resource for precision medicine that provides accessible information to patients and physicians ...
By providing the most comprehensive, up-to-date exome design, these new products will enable researchers to delve deeper into both constitutional diseases and cancers. "The SureSelect exome has been widely adopted in both clinical and translational research, and it has greatly enabled discovery of disease-causing genes," said Jacob Thaysen, president of Agilent's Diagnostics and ...
Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer — mesothelioma, and melanoma of the eye. ...